Security
Alpha Tau Medical Ltd. Warrant · DRTSW
DRTSWNASDAQWarrantCurrentCIK 1871321Updated Nov 20, 2026
DRTSW price & chart
Loading TradingView…
NASDAQ:DRTSW on TradingView ↗About the company
Alpha DaRT® (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| AssetsUSD | 110,954,000Source | 96,048,000Source | 111,206,000Source | — | 105,652,000Source | 86,204,000Source | 107,388,000Source | 120,149,000Source |
| Property, Plant and Equipment, NetUSD | 17,285,000Source | 12,354,000Source | 7,549,000Source | — | 19,661,000Source | 13,934,000Source | 12,798,000Source | 7,471,000Source |
| Current assets: | ||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 11,703,000Source | 2,763,000Source | 855,000Source | — | 12,202,000Source | 13,724,000Source | 12,657,000Source | 5,836,000Source |
| Assets, CurrentUSD | 85,778,000Source | 75,248,000Source | 96,059,000Source | — | 78,298,000Source | 64,229,000Source | 85,756,000Source | 106,477,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,525,000Source | 1,102,000Source | 1,698,000Source | — | 1,395,000Source | 1,374,000Source | 816,000Source | 1,097,000Source |
| Operating Lease, Right-of-Use AssetUSD | 7,428,000Source | 8,009,000Source | 7,157,000Source | — | 7,214,000Source | 7,609,000Source | 8,363,000Source | 5,810,000Source |
| LIABILITIES AND EQUITY | ||||||||
| LiabilitiesUSD | 24,331,000Source | 22,031,000Source | 18,643,000Source | — | 28,553,000Source | 23,538,000Source | 22,913,000Source | 14,492,000Source |
| Stockholders’ equity: | ||||||||
| Additional Paid in CapitalUSD | — | — | 196,045,000Source | — | — | — | 200,234,000Source | 192,259,000Source |
| Retained Earnings (Accumulated Deficit)USD | -166,314,000Source | -131,109,000Source | -103,482,000Source | — | -190,136,000Source | -147,509,000Source | -115,759,000Source | -86,602,000Source |
| Stockholders' Equity Attributable to ParentUSD | 86,623,000Source | 74,017,000Source | 92,563,000Source | 108,268,000Source | 77,099,000Source | 62,666,000Source | 84,475,000Source | 105,657,000Source |
| Additional Paid in Capital, Common StockUSD | 252,937,000Source | 205,126,000Source | — | — | 267,235,000Source | 210,175,000Source | — | — |
| Liabilities and EquityUSD | 110,954,000Source | 96,048,000Source | 111,206,000Source | — | 105,652,000Source | 86,204,000Source | 107,388,000Source | 120,149,000Source |
| Current liabilities: | ||||||||
| Liabilities, CurrentUSD | 8,156,000Source | 6,456,000Source | 5,416,000Source | — | 10,507,000Source | 8,675,000Source | 7,102,000Source | 4,338,000Source |
| Operating Lease, Liability, CurrentUSD | 1,080,000Source | 1,038,000Source | 846,000Source | — | 1,131,000Source | 1,011,000Source | 1,062,000Source | 669,000Source |
| Accounts Payable, CurrentUSD | — | — | 1,789,000Source | — | — | — | 2,566,000Source | 1,423,000Source |
| Operating Lease, Liability, NoncurrentUSD | 6,201,000Source | 6,109,000Source | 5,433,000Source | — | 6,243,000Source | 5,964,000Source | 6,604,000Source | 4,524,000Source |
| Additional Financial Items | ||||||||
| Accrued Liabilities, CurrentUSD | — | — | — | — | 3,784,000Source | 2,615,000Source | 2,236,000Source | 1,276,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 83,253,000Source | 74,146,000Source | — | — | 76,903,000Source | 62,855,000Source | 84,940,000Source | — |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | 1,025,000Source | — | — | — |
| Short-term InvestmentsUSD | 67,996,000Source | 68,268,000Source | 92,672,000Source | — | 60,924,000Source | 45,876,000Source | 69,131,000Source | 98,694,000Source |
| Other Assets, Noncurrent | — | — | —Source | — | — | — | — | — |
cash flow · annual statements
| Line item | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | 10,617,000Source | 9,916,000Source | 7,926,000Source | 6,748,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | 97,000Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | -26,681,000Source | -19,783,000Source | -17,958,000Source | -23,879,000Source |
| Cash flows from investing activities: | ||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | -20,588,000Source | 20,768,000Source | 18,682,000Source | -89,936,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | 6,075,000Source | 2,238,000Source | 6,401,000Source | 904,000Source |
| Cash flows from financing activities: | ||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | 45,768,000Source | 25,000Source | 5,297,000Source | 96,905,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | -1,522,000Source | 1,067,000Source | 5,971,000Source | -17,168,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 11,703,000Source | 2,763,000Source | 1,689,000Source | 12,363,000Source | 12,202,000Source | 13,724,000Source | 12,657,000Source | 6,686,000Source |
| Supplemental disclosure of cash flow information: | ||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | 381,000Source | 321,000Source | 52,000Source | 237,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | -21,000Source | 57,000Source | -50,000Source | -258,000Source |
| Additional Financial Items | ||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | — | 10,617,000Source | 9,916,000Source | 7,926,000Source | 6,748,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 83,253,000Source | 74,146,000Source | — | — | 76,903,000Source | 62,855,000Source | 84,940,000Source | — |
| DepreciationUSD | — | — | — | — | 1,232,000Source | 1,102,000Source | 1,074,000Source | 979,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | 106,000Source | — | 413,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | -35,000Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | — | — | 8,363,000Source | 6,673,000Source | 7,332,000Source | 10,272,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | — | — | — | — | — | -33,762,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | 33,762,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | 121,000Source | 6,000Source | 16,000Source | 20,000Source |
| InterestExpenseNonoperatingUSD | — | — | — | — | 347,000Source | 303,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | — | — | -42,627,000Source | -31,750,000Source | -29,157,000Source | -33,762,000Source |
| Nonoperating Income (Expense)USD | — | — | — | — | -218,000Source | 4,298,000Source | 6,539,000Source | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | 45,496,000Source | — | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | 272,000Source | 25,000Source | 49,000Source | 27,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -42,288,000Source | -36,042,000Source | -35,680,000Source | -32,136,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -42,506,000Source | -31,744,000Source | -29,141,000Source | -33,742,000Source |
| Income Tax Expense (Benefit)USD | 121,000Source | 6,000Source | 16,000Source | 20,000Source |
| Net Income (Loss) Attributable to ParentUSD | -42,627,000Source | -31,750,000Source | -29,157,000Source | -33,762,000Source |
| Earnings Per Share, BasicUSD per share | -0.53Source | -0.45Source | -0.42Source | -0.53Source |
| Earnings Per Share, DilutedUSD per share | -0.53Source | -0.45Source | -0.42Source | -0.53Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 80,581,440Source | 69,927,566Source | 69,377,922Source | 63,534,875Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 80,581,440Source | 69,927,566Source | 69,377,922Source | 63,534,875Source |
| Interest Expense (non-operating)USD | 347,000Source | 303,000Source | — | — |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | 24,000Source | — | 16,000Source | 20,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | 106,000Source | — | 413,000Source |
| General and Administrative ExpenseUSD | 8,363,000Source | 6,673,000Source | 7,332,000Source | 10,272,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | — | -33,762,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -42,331,000Source | -31,065,000Source | 28,224,000Source | 33,100,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | 33,762,000Source |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | — | — | — | -0.53Source |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | — | — | — | -0.53Source |
| Nonoperating Income (Expense)USD | -218,000Source | 4,298,000Source | 6,539,000Source | — |
| Other ExpensesUSD | — | — | — | 16,547Source |
| Research and Development ExpenseUSD | 32,065,000Source | 27,020,000Source | 26,424,000Source | 20,890,000Source |
Offerings
Registration 333-295359
Filing attachments
ea031235801ex99-1.htm · 6-K · 2026-11-19
Exhibit 99.1 Alpha Tau Announces Third Quarter 2026 Financial Results and Provides Corporate Update - New interim results from the U.S. REGAIN recurrent glioblastoma trial presented at the SNO 2026 Annual Meeting: all eight treated patients alive, with median overall survival not reached, and a 100% objective response rate, including five complete responses, in the first six evaluable patients at 6.9 months median follow-up, with 100% feasibility and no unanticipated serious adverse events - …
Read attachment ↗ea031237801ex99-1.htm · 6-K · 2026-11-16
Exhibit 99.1 N A S D A Q / T A S E · D R T S R E G A I N · I N T E R I M R E S U L T S A S O F N O V 1 1, 2 0 2 6 Alpha DaRT in the brain. Interim results as of November 11, 2026 from REGAIN, the U.S. trial of Alpha DaRT in recurrent glioblastoma, as presented at the SNO 2026 Annual Meeting. 8 of 8 patients alive · 100% feasibility · 6 of 6 objective responses in assessed patients 1 D I S C L A I M E R Important notices. This presentation (together with oral statements made in connection herew…
Read attachment ↗ea031236301ex99-1.htm · 6-K · 2026-11-16
Exhibit 99.1 Alpha Tau Announces New Positive Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial: All Patients Treated are Alive with Median Survival Not Reached, 6.9 Months Median Follow-Up in the First Six Evaluable Patients With 100% ORR, 100% Feasibility and No Unanticipated Serious Adverse Events - Conference Call Scheduled for 8:30am ET November 16 - All eight treated brain cancer patients in the trial remain alive as of November 11, 2026; median overall survival has …
Read attachment ↗ea031155201ex99-1.htm · 6-K · 2026-11-12
Exhibit 99.1 Alpha Tau to Host Investor Call to Review New Data from the Alpha DaRT® Recurrent Glioblastoma REGAIN Trial - Call to Follow Presentation of New Data at Upcoming Society for Neuro- Oncology SNO Conference - JERUSALEM, Nov. 12, 2026 -- Alpha Tau Medical Ltd. (Nasdaq/TASE: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that it will host a conference call and webcast on Monday, Nov. 16, 2026, at 8:30 a.m. ET t…
Read attachment ↗ea031012301ex99-1.htm · 6-K · 2026-10-29
Exhibit 99.1 Alpha Tau Announces Inclusion in the Flagship TA-90 and TA-125 Indices of the Tel Aviv Stock Exchange Funds that track these TASE benchmark indexes are expected to add Alpha Tau shares to their holdings TA-125 tracks the 125 largest and most prominent companies on the TASE JERUSALEM, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq and TASE: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced tha…
Read attachment ↗ea030933001ex99-1.htm · 6-K · 2026-10-22
Exhibit 99.1 Alpha Tau and Samsung Medical Center Sign MOU to Explore Clinical Trial of Alpha DaRT ® for Pancreatic Cancer Patients in Korea - MOU relates to a potential clinical trial in South Korea, Alpha DaRT’s first, at Samsung Medical Center (SMC) in Seoul, ranked fifth in the world and number one in Korea in oncology - - In Korea, only about one in five pancreatic cancer patients undergo surgery, and the disease’s death rate rose over 6% in 2025, the steepest increase among major cancer…
Read attachment ↗